Table of Contents
- History Made: First Drug to Beat Immunotherapy in Head-to-Head Trial
- HARMONi-6 Trial Results: A Clear Winner
- What is Ivonescimab? A Dual-Action Breakthrough
- How Many Patients Could This Impact?
- Global Development: FDA Submission Underway
- Chinese Innovation Reaches New Heights
- Sources
History Made: First Drug to Beat Immunotherapy in Head-to-Head Trial {#history-made}
For the first time in cancer treatment history, a new drug has demonstrated a statistically significant overall survival benefit over standard immunotherapy plus chemotherapy in first-line non-small cell lung cancer (NSCLC). The breakthrough comes from an unlikely source: a Chinese biopharmaceutical company called Akeso, whose drug ivonescimab has just delivered results that are sending shockwaves through the global oncology community.
Presented at the plenary session of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the Phase III HARMONi-6 trial showed that ivonescimab combined with chemotherapy reduced the risk of death by 34% compared to tislelizumab (a PD-1 inhibitor similar to Keytruda) plus chemotherapy in patients with advanced squamous NSCLC.
HARMONi-6 Trial Results: A Clear Winner {#trial-results}
The numbers are striking. In a study of 532 patients across 50 hospitals in China:
- Median Overall Survival: 27.89 months (ivonescimab + chemo) vs 23.69 months (tislelizumab + chemo)
- 24-Month Survival Rate: 64.7% vs 48.6%
- Hazard Ratio: 0.66 (95% CI: 0.50-0.87; p=0.0017)
- Death Risk Reduction: 34%
The benefit was consistent across all subgroups, including both PD-L1 positive and PD-L1 negative patients, suggesting that ivonescimab could become a new standard of care regardless of biomarker status.
Dr. Shun Lu, Chief of Shanghai Lung Cancer Center at Shanghai Chest Hospital and the study’s lead presenter, noted that prior to HARMONi-6, no Phase III trial had shown a statistically significant OS improvement over PD-(L)1 inhibitor plus chemotherapy in a head-to-head setting.
What is Ivonescimab? A Dual-Action Breakthrough {#what-is-ivonescimab}
Ivonescimab represents a new class of cancer therapy: a bispecific antibody that simultaneously targets two pathways—PD-1 and VEGF. This dual mechanism allows the drug to both activate the immune system against cancer cells and cut off the tumor’s blood supply.
Historically, combining anti-PD-1 and anti-VEGF therapies separately in squamous NSCLC has been challenging due to severe toxicity, including life-threatening hemorrhage. Ivonescimab’s unique design appears to overcome this limitation, with a manageable safety profile in the HARMONi-6 trial.
The drug is being developed by Akeso, Inc., a Chinese biopharmaceutical company, with Summit Therapeutics holding commercialization rights for the U.S., Europe, and Japan. The drug has already received NMPA approval in China for certain NSCLC indications.
How Many Patients Could This Impact? {#patients-impacted}
Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases, with squamous NSCLC representing about 30% of NSCLC patients. Globally, this means millions of patients could potentially benefit from this new treatment option.
In China alone, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. The HARMONi-6 trial enrolled patients from 50 hospitals across the country, demonstrating the scale of China’s clinical trial infrastructure.
For international patients considering treatment options, ivonescimab represents a new frontier—particularly for those whose tumors do not respond to standard immunotherapy or who need more effective first-line options.
Global Development: FDA Submission Underway {#global-development}
Summit Therapeutics has already submitted a Biologics License Application (BLA) to the U.S. FDA seeking approval for ivonescimab in combination with chemotherapy for patients with EGFR-mutant NSCLC after TKI therapy (the HARMONi trial). The FDA accepted the BLA in January 2026.
Multiple global Phase III trials are ongoing, including HARMONi-3 and HARMONi-7, which are comparing ivonescimab directly to Keytruda-based regimens in different patient populations. These trials will provide crucial data for broader regulatory approvals.
Dr. Maky Zanganeh, President and Co-CEO of Summit, stated: “For the first time, a Phase III clinical study has demonstrated a statistically significant overall survival benefit in front-line driver-mutation-negative non-small cell lung cancer compared to anti-PD-1 therapy in combination with chemotherapy.”
Chinese Innovation Reaches New Heights {#chinese-innovation}
The ivonescimab success story is part of a larger trend: China’s rapid emergence as a biopharmaceutical powerhouse. In 2025, China accounted for 30.5% of the global pipeline of innovative drug candidates—just 2.5 percentage points behind the United States.
Chinese biotechs generated a record $135.7 billion in license-out transaction value in 2025, nearly triple the $51.9 billion recorded in 2024. In May 2025, Pfizer paid a record $1.25 billion upfront—the largest such payment ever for a Chinese-origin asset—to license 3SBio’s PD-1/VEGF cancer immunotherapy.
As Pfizer CEO Albert Bourla warned in March 2026: “U.S. dominance in biotech technology is being challenged by a competitor, and that’s China.” The ivonescimab results validate that warning—and signal a new era in global drug development.
Sources {#sources}
- Akeso Official News: Ivonescimab Phase III HARMONi-6 Study Results (ASCO 2026)
- CIRSD: A Biopharmaceutical Superpower: China’s Rise, Its Limits, And What Comes Next
- Akeso, Inc. Official Website
- Summit Therapeutics Official Website
omuat.com is a healthcare information platform providing news about medical innovations available in China. This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional for treatment decisions.
Images: Pixabay (royalty-free)